Hydroxamic acid derivatives

Abstract

The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.

What is claimed is: 
     
       1. A compound of Formula I, or a pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof wherein
 Z is deleted absent, C(R a R b ), O, S, C(O), N(R a ), SO 2 , OC(O), C(O)O, OSO 2 , S(O 2 )O, C(O)S, SC(O), C(O)C(O), C(O)N(R a ), N(R a )C(O), S(O 2 )N(R a ), N(R a )S(O 2 ), OC(O)N(R a ), N(R a )C(O)O, N(R a )C(O)S, or N(R a )C(O)N(R b ), in which each of R a  and R b , independently, is H, alkyl, alkenyl, or alkynyl;   m is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16; and   P is   
       
         
           
           
               
               
           
         
       
       in which each of X 1  and X 2  independently, is halo or OSO 2 R c , in which R c  is alkyl, alkenyl, or alkynyl; Q is cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl, each of which, independently, is optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, halo, nitro, oxo, —C═NH, cyano, OR d , OC(O)R d , OC(O)OR d , OC(O)SR d , SR d , C(O)R d , C(O)OR d , C(O)SR d , C(O)NR e R f , SOR d , SO 2 R d , NR e R f , or N(R e )C(O)R f , in which each of R d , R e , and R f , independently, is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, cyano, nitro, hydroxy, or alkoxy. 
     
     
       2. The compound or salt of  claim 1 , wherein Z is deleted absent, CH 2 , O, CO, NH, SO 2 , OC(O), C(O)O, C(O)S, NHC(O), C(O)NH, OC(O)NH, NHC(O)O, or NHC(O)S; m is 5, 6, 7, or 8. 
     
     
       3. The compound or salt of  claim 2 , wherein Q is an aryl or heteroaryl. 
     
     
       4. The compound or salt of  claim 3 , wherein Q is a 9-10 membered aryl or heteroaryl. 
     
     
       5. The compound or salt of  claim 4 , wherein P is 
       
         
           
           
               
               
           
         
       
     
     
       6. The compound or salt of  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
       7. A pharmaceutical composition comprising a compound or salt of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
       8. A method of improving or relieving multiple myeloma, the method comprising administering to a subject in need thereof an effective amount of a compound or salt of  claim 1 . 
     
     
       9. A method of improving or relieving multiple myeloma, the method comprising administering to a subject in need thereof an effective amount of a compound or salt of  claim 5 . 
     
     
       10. A method of improving or relieving multiple myeloma, the method comprising administering to a subject in need thereof an effective amount of a compound or salt of  claim 6 . 
     
     
       11. The compound or salt of  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
       12. A method of improving or relieving multiple myeloma, the method comprising administering to a subject in need thereof an effective amount of a compound or salt of  claim 11 . 
     
     
       13. A pharmaceutical composition comprising a compound or salt of  claim 5  and a pharmaceutically acceptable carrier. 
     
     
       14. A pharmaceutical composition comprising a compound or salt of  claim 6  and a pharmaceutically acceptable carrier. 
     
     
       15. A pharmaceutical composition comprising a compound or salt of  claim 11  and a pharmaceutically acceptable carrier. 
     
     
       16. The compound or salt of  claim 6 , wherein the salt is a chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, or acetate salt. 
     
     
       17. The compound or salt of claim 6, wherein the compound is a hydrochloric acid salt. 
     
     
       18. The compound or salt of claim 6, wherein the compound is an acetate salt.